|premium|

INO Stock Price: Inovio Pharmaceuticals Inc. crashes after sharp analyst downgrade

  • NASDAQ:INO plummets over 15% during Thursday’s trading session.
  • Shares corrected after surging over 80% last week after a presentation on its proposed COVID-19 vaccine.
  • Roth Capital analyst gives severe downgrade to the stock.

NASDAQ:INO investors have been taken for quite the ride over the past two weeks with shares peaking at $18.50 while also bottoming out in the single digits. The catalyst for the recent spike was a presentation that the pharmaceutical company released for investors about the potential of its new coronavirus vaccine candidate INO-4800. While the promotional video seemed to strike the right note with investors, Wall Street analysts remained skeptical. Shares are still up over 650% over the past 52-weeks but investors have to wonder if the stock has gained as much as it will for the time being.

Roth Capital analyst Jonathan Aschoff did not mix his words when he gave a severe downgrade of $11 to Inovio’s price target and doubled down on his sell rating for the biotech firm. Aschoff affirms that INO-4800 has “virtually no chance” of winning the Operation Warp Speed race and had just as little optimism for Inovio’s HPV cancer treatment, VGX-3100, as well. After Aschoff’s downgrade, shares tumbled showing just how much power these analysts have over the price of company stocks

INO stock news

INO stock price chart

Whether or not Aschoff’s claims are warranted it seems as though investors are buying into the analyst’s downgrade. The more damning thing about INO-4800 could be that the vaccine candidate is still in Phase 1 of its clinical trials whereas vaccine candidates from other companies like AstraZeneca (NYSE:AZN), Moderna (NASDAQ:MRNA), and Pfizer (NYSE:PFE) are all in at least Phase 3 of their respective trials. This means that the timeline for an actual vaccine may still more than a year off as rival firms bring their vaccines to market. 

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to PremiumSign In

Author

More from Stocks Reporter
Share:

Editor's Picks

EUR/USD holds gains around 1.1800 amid renewed USD selling

EUR/USD regains positive traction and holds around 1.1800 in the European session, reversing the previous day's modest losses. The pair's uptick is sponsored by the emergence of fresh US Dollar selling, which remains induced by persistent trade-related uncertainties. 

GBP/USD strengthens above 1.3500 on softer US Dollar

GBP/USD is posting moderate gains above 1.3500 in European trading on Wednesday. The pair appreciates as the US Dollar meets fresh supply following US President Donald Trump’s first State of the Union address and amid looming tariff uncertainty. 

Gold eyes monthly top above $5,200 amid geopolitics, trade jitters

Gold buyers are back in the game, eyeing $5,200 and beyonf on Wednesday after seeing a correction from monthly highs on Tuesday. The US Dollar slips after Trump’s SOTU fails to impress and as AI-driven worries ease. Dovish Fed bets also weigh.  Gold looks north so long as the key 61.8% Fibo resistance at $5,142 holds on the daily chart.

Bitcoin, Ethereum and Ripple post cautious recovery amid downside risks

Bitcoin, Ethereum, and Ripple are posting a cautious recovery on Wednesday following a market correction earlier this week.  BTC is approaching a key breakdown level, while ETH and XRP are rebounding from crucial support levels.

Nvidia remains at the heart of the AI boom

Nvidia remains at the heart of the AI boom, with Q4 revenue projected near $65.6–66.1 billion, nearly 70% higher year-over-year. But investors are watching cash flow, leverage, and broader AI adoption. Growth is strong, but the AI stress isn’t over.

Cosmos Hub Price Forecast: ATOM rebounds slightly, bearish outlook remains intact

Cosmos Hub (ATOM) price rebounds, trading above $2.05 at the time of writing on Wednesday, after undergoing a sharp correction since last week. Weakening on-chain and derivatives data support a bearish outlook, while technical analysis remains unfavorable.